Stryker Co. (NYSE:SYK) Shares Purchased by Watch Point Trust Co

Watch Point Trust Co grew its stake in shares of Stryker Co. (NYSE:SYK) by 8.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,190 shares of the medical technology company’s stock after acquiring an additional 1,878 shares during the period. Stryker accounts for 2.7% of Watch Point Trust Co’s holdings, making the stock its 7th largest position. Watch Point Trust Co’s holdings in Stryker were worth $4,768,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. D.B. Root & Company LLC raised its position in shares of Stryker by 3.0% in the second quarter. D.B. Root & Company LLC now owns 1,724 shares of the medical technology company’s stock valued at $354,000 after buying an additional 50 shares in the last quarter. Independence Bank of Kentucky increased its stake in Stryker by 4.9% in the first quarter. Independence Bank of Kentucky now owns 1,180 shares of the medical technology company’s stock valued at $233,000 after acquiring an additional 55 shares during the last quarter. Benedict Financial Advisors Inc. increased its stake in Stryker by 1.1% in the first quarter. Benedict Financial Advisors Inc. now owns 5,235 shares of the medical technology company’s stock valued at $1,034,000 after acquiring an additional 57 shares during the last quarter. Berman Capital Advisors LLC increased its stake in Stryker by 11.1% in the first quarter. Berman Capital Advisors LLC now owns 571 shares of the medical technology company’s stock valued at $112,000 after acquiring an additional 57 shares during the last quarter. Finally, Bailard Inc. increased its stake in Stryker by 0.6% in the second quarter. Bailard Inc. now owns 9,219 shares of the medical technology company’s stock valued at $1,895,000 after acquiring an additional 57 shares during the last quarter. Hedge funds and other institutional investors own 73.48% of the company’s stock.

Shares of NYSE SYK traded up $3.35 during midday trading on Thursday, reaching $215.41. 16,381 shares of the company were exchanged, compared to its average volume of 1,090,678. The company’s 50-day moving average price is $210.23. The stock has a market capitalization of $81.21 billion, a PE ratio of 29.38, a P/E/G ratio of 2.64 and a beta of 0.85. Stryker Co. has a one year low of $144.75 and a one year high of $222.59. The company has a current ratio of 2.07, a quick ratio of 1.26 and a debt-to-equity ratio of 0.67.



Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 25th. The medical technology company reported $1.98 earnings per share for the quarter, topping analysts’ consensus estimates of $1.93 by $0.05. Stryker had a net margin of 24.99% and a return on equity of 25.98%. The firm had revenue of $3.65 billion for the quarter, compared to analysts’ expectations of $3.60 billion. During the same quarter in the previous year, the firm posted $1.76 earnings per share. The company’s revenue was up 9.9% on a year-over-year basis. Analysts forecast that Stryker Co. will post 8.2 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be paid a $0.52 dividend. The ex-dividend date is Friday, September 27th. This represents a $2.08 annualized dividend and a dividend yield of 0.97%. Stryker’s dividend payout ratio is 28.45%.

In related news, CFO Glenn S. Boehnlein sold 2,700 shares of the business’s stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $214.16, for a total value of $578,232.00. Following the sale, the chief financial officer now owns 20,633 shares of the company’s stock, valued at $4,418,763.28. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Allan C. Golston sold 3,399 shares of the business’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $209.84, for a total transaction of $713,246.16. Following the completion of the sale, the director now directly owns 13,762 shares in the company, valued at approximately $2,887,818.08. The disclosure for this sale can be found here. In the last three months, insiders sold 15,431 shares of company stock worth $3,174,489. 7.20% of the stock is currently owned by insiders.

A number of research analysts recently issued reports on SYK shares. Wells Fargo & Co lifted their price objective on shares of Stryker from $219.00 to $228.00 and gave the company an “outperform” rating in a research note on Tuesday, July 2nd. Canaccord Genuity lifted their price objective on shares of Stryker from $195.00 to $233.00 and gave the company a “buy” rating in a research note on Friday, July 26th. BMO Capital Markets set a $216.00 price objective on shares of Stryker and gave the company a “hold” rating in a research note on Friday, July 26th. Piper Jaffray Companies lifted their price objective on shares of Stryker from $205.00 to $240.00 and gave the company an “overweight” rating in a research note on Friday, July 26th. Finally, Raymond James set a $240.00 price objective on shares of Stryker and gave the company a “buy” rating in a research note on Friday, July 26th. Five research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $214.89.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Story: Why is the price target of stocks important?

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.